Tryptophan pathway profiling in multiple sclerosis patients treated with ocrelizumab
Our data points out to concurrent alterations of Trp-related pathways among both OCR treated and untreated MS patients. Furthermore, MS treated patients presented a pattern resembling health state for various metabolites across the pathways. The results reported in our research may contribute to unveiling new perspectives and understanding regarding MS pathogenetic mechanisms.
Authors
- Daniela Cargnelutti
- Viviana Valeri
- Barbara Frossi (ORCID: https://orcid.org/0000-0001-9855-2396)
- Eleonora Martinis (ORCID: https://orcid.org/0000-0002-2667-6530)
- Simone Lorenzut (ORCID: https://orcid.org/0000-0001-9516-5956)
- Silvia Tonon (ORCID: https://orcid.org/0000-0002-3361-2906)
- Nicola Giacchè (ORCID: https://orcid.org/0000-0002-4810-3960)
- Carolina Colliva (ORCID: https://orcid.org/0000-0002-1675-3141)
- Carolina Ricci
- Matteo Pivetta
Institutions
- University of Udine (IT)
- Abiogen Pharma (Italy) (IT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-09
- DOI
- https://doi.org/10.3389/fimmu.2025.1603663
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47